Skip to main content

Articles

Page 1 of 67

  1. Clear cell renal cell carcinoma (ccRCC), with its hallmark phenotype of high cytosolic lipid content, is considered a metabolic cancer. Despite the implication of this lipid-rich phenotype in ccRCC tumorigenes...

    Authors: Tin Tin Manh Nguyen, Thi Ha Nguyen, Han Sun Kim, Thien T. P. Dao, Yechan Moon, Munjun Seo, Sunmi Kang, Van-Hieu Mai, Yong Jin An, Cho-Rok Jung, Jin-Mo Kim and Sunghyouk Park
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:42
  2. The response rate to immunotherapy in patients with bladder cancer (BCa) remains relatively low. Considering the stable existence and important functions in tumour metabolism, the role of circRNAs in regulatin...

    Authors: Jiancheng Lv, Kai Li, Hao Yu, Jie Han, Juntao Zhuang, Ruixi Yu, Yidong Cheng, Qiang Song, Kexin Bai, Qiang Cao, Haiwei Yang, Xiao Yang and Qiang Lu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:41
  3. Lymph node and distant metastasis contribute to poor outcomes in patients with oral squamous cell carcinoma (OSCC). The mechanisms regulating cancer migration and invasion play a key role in OSCC.

    Authors: Sheng-Yen Hsiao, Shang-Mei Weng, Jenn-Ren Hsiao, Yi-Ying Wu, Jia-En Wu, Chia-Hao Tung, Wan-Lin Shen, Shu-Fang Sun, Wen-Tsung Huang, Cheng-Yao Lin, Shang-Hung Chen, Tse-Ming Hong, Yuh-Ling Chen and Jang-Yang Chang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:40
  4. Recurrence of retinoblastoma (RB) following chemoreduction is common and is often managed with local (intra-arterial/intravitreal) chemotherapy. However, some tumors are resistant to even local administration ...

    Authors: Atthapol Srimongkol, Natanan Laosillapacharoen, Duangporn Saengwimol, Vijender Chaitankar, Duangnate Rojanaporn, Thanastha Thanomchard, Suparerk Borwornpinyo, Suradej Hongeng and Rossukon Kaewkhaw
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:39
  5. Hepatic inflammation is a common initiator of liver diseases and considered as the primary driver of hepatocellular carcinoma (HCC). However, the precise mechanism of inflammation-induced HCC development and i...

    Authors: Yunzhi Liu, Qishan Xu, Fan Deng, Zhuojun Zheng, Jialiang Luo, Ping Wang, Jia Zhou, Xiao Lu, Liyun Zhang, Zhengliang Chen, Qifan Zhang, Qingyun Chen and Daming Zuo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:38
  6. A pharmacogenomic platform using patient-derived cells (PDCs) was established to identify the underlying resistance mechanisms and tailored treatment for patients with advanced or refractory lung cancer.

    Authors: Namhee Yu, Mihwa Hwang, Youngjoo Lee, Bo Ram Song, Eun Hye Kang, Hanna Sim, Beung-Chul Ahn, Kum Hui Hwang, Jihyun Kim, Sehwa Hong, Sunshin Kim, Charny Park and Ji-Youn Han
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:37
  7. Genetic background plays an important role in the occurrence and development of gastric cancer (GC). With the application of genome-wide association study (GWAS), an increasing number of tumor susceptibility g...

    Authors: Yuqi Chen, Wenying Yan, Kexi Yang, Yiting Qian, Yanjun Chen, Ruoqin Wang, Jinghan Zhu, Yuxin He, Hongya Wu, Guangbo Zhang, Tongguo Shi and Weichang Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:36
  8. Breast cancer is the most frequently diagnosed cancer and a common cause of cancer-related death in women. It is well recognized that obesity is associated with an enhanced risk of more aggressive breast cance...

    Authors: Andreas Ritter, Nina-Naomi Kreis, Susanne Roth, Alexandra Friemel, Babek Kahn Safdar, Samira Catharina Hoock, Julia Maria Wildner, Roman Allert, Frank Louwen, Christine Solbach and Juping Yuan
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:35
  9. Metabolic reprogramming is a hallmark of various cancers. Targeting metabolic processes is a very attractive treatment for cancer. Renal cell carcinoma (RCC) is a type of metabolic disease, and the lipidomic p...

    Authors: Xintian Chen, Hongmei Yong, Miaolei Chen, Chuyin Deng, Pengfei Wang, Sufang Chu, Minle Li, Pingfu Hou, Junnian Zheng, Zhongwei Li and Jin Bai
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:34
  10. With increasing incidence and mortality, colorectal cancer (CRC) seriously endangers human health. LARP6, a member of La-related protein (LARP) family, is a RNA binding protein and probably associates with CRC pr...

    Authors: Xiaoli Long, Xunhua Liu, Ting Deng, Jianxiong Chen, Jiawen Lan, Sijing Zhang, Miao Zhou, Dan Guo and Jun Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:33
  11. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-020-01697-6.

    Authors: Mingming Jin, Shengjie Lu, Yue Wu, Chen Yang, Chunzi Shi, Yanqiu Wang and Gang Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:32
  12. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-018-1010-1.

    Authors: Yingxia Ning, Weifeng Feng, Xiaocheng Cao, Kaiqun Ren, Meifang Quan, A. Chen, Chang Xu, Yebei Qiu, Jianguo Cao, Xiang Li and Xin Luo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:30
  13. The applicability and therapeutic efficacy of specific personalized immunotherapy for cancer patients is limited by the genetic diversity of the host or the tumor. Side-effects such as immune-related adverse e...

    Authors: Chia-Hung Chen, Tzu-Han Weng, Hsiao-Hsuan Huang, Ling-Ya Huang, Kai-Yao Huang, Pin-Rong Chen, Kuang-Yu Yeh, Chi-Ting Huang, Yu-Tzu Chien, Po-Ya Chuang, Yu-Ling Lin, Nu-Man Tsai, Shih-Jen Liu, Yu-Cheng Su, Shun-Long Weng and Kuang-Wen Liao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:29
  14. Cervical cancer (CC) is the 3rd most common cancer in women and the 4th leading cause of deaths in gynaecological malignancies, yet the exact progression of CC is inconclusive, mainly due to the high complexity o...

    Authors: Xiaosong Liu, Guoying Ni, Pingping Zhang, Hejie Li, Junjie Li, Bernardo Cavallazzi Sebold, Xiaolian Wu, Guoqiang Chen, Songhua Yuan and Tianfang Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:28
  15. Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Unlike many other cancers, PM is mostly characterized by inactivation of tumor suppressor genes. Its highly malignant nature in absence o...

    Authors: Alexander Ries, Daniela Flehberger, Astrid Slany, Christine Pirker, Johanna C. Mader, Thomas Mohr, Karin Schelch, Katharina Sinn, Berta Mosleh, Mir Alireza Hoda, Balazs Dome, Helmut Dolznig, Georg Krupitza, Leonhard Müllauer, Christopher Gerner, Walter Berger…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:27
  16. Individuals with certain chronic inflammatory lung diseases have a higher risk of developing lung cancer (LC). However, the underlying mechanisms remain largely unknown. Here, we hypothesized that chronic expo...

    Authors: Dongjie Wang, Wen Li, Natalie Albasha, Lindsey Griffin, Han Chang, Lauren Amaya, Sneha Ganguly, Liping Zeng, Bora Keum, José M. González-Navajas, Matt Levin, Zohreh AkhavanAghdam, Helen Snyder, David Schwartz, Ailin Tao, Laela M. Boosherhri…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:26
  17. Intrinsic or acquired resistance to HER2-targeted therapy is often a problem when small molecule tyrosine kinase inhibitors or antibodies are used to treat patients with HER2 positive breast cancer. Therefore,...

    Authors: Magdalena Keller, Katharina Rohlf, Annika Glotzbach, Gregor Leonhardt, Simon Lüke, Katharina Derksen, Özlem Demirci, Defne Göçener, Mohammad AlWahsh, Jörg Lambert, Cecilia Lindskog, Marcus Schmidt, Walburgis Brenner, Matthias Baumann, Eldar Zent, Mia-Lisa Zischinsky…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:25
  18. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-020-01657-0.

    Authors: Xiang Zhang, Dawei Wang, Boke Liu, Xingwei Jin, Xianjin Wang, Junwei Pan, Weichao Tu and Yuan Shao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:24
  19. Authors: Jiahui Xu, Deying Liu, Huilin Niu, Guifang Zhu, Yangwei Xu, Danli Ye, Jian Li and Qingling Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:23

    The original article was published in Journal of Experimental & Clinical Cancer Research 2017 36:19

  20. Nitric oxide-releasing drugs are used for cardiovascular diseases; however, their effects on the tumor immune microenvironment are less clear. Therefore, this study explored the impact of nitric oxide donors o...

    Authors: Chung-Yen Li, Gangga Anuraga, Chih-Peng Chang, Tzu-Yang Weng, Hui-Ping Hsu, Hoang Dang Khoa Ta, Pei-Fang Su, Pin-Hsuan Chiu, Shiang-Jie Yang, Feng-Wei Chen, Pei-Hsuan Ye, Chih-Yang Wang and Ming-Derg Lai
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:22
  21. Characterization of clinical phenotypes in context with tumor and host genomic information can aid in the development of more effective and less toxic risk-adapted and targeted treatment strategies. To analyze...

    Authors: Stefanie V. Junk, Elke Schaeffeler, Martin Zimmermann, Anja Möricke, Rita Beier, Peter Schütte, Birthe Fedders, Julia Alten, Laura Hinze, Norman Klein, Andreas Kulozik, Martina U. Muckenthaler, Rolf Koehler, Arndt Borkhardt, Jayaram Vijayakrishnan, David Ellinghaus…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:21
  22. Tumor progression is based on a close interaction between cancer cells and Tumor MicroEnvironment (TME). Here, we focus on the role that Cancer Associated Fibroblasts (CAFs), Mesenchymal Stem Cells (MSCs) and ...

    Authors: Francesca Orso, Federico Virga, Daniela Dettori, Alberto Dalmasso, Mladen Paradzik, Aurora Savino, Margherita A. C. Pomatto, Lorena Quirico, Stefania Cucinelli, Martina Coco, Katia Mareschi, Franca Fagioli, Leonardo Salmena, Giovanni Camussi, Paolo Provero, Valeria Poli…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:20
  23. Striatin interacting protein 2 (STRIP2) is a core component of the striatin-interacting phosphatase and kinase (STRIPAK) complexes, which is involved in tumor initiation and progression via the regulation of c...

    Authors: Xilin Zhang, Qiuqiang Chen, Ying He, Qian Shi, Chengyi Yin, Yanping Xie, Huanming Yu, Ying Bao, Xiang Wang, Chengwu Tang and Zhaohui Dong
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:19
  24. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-016-0301-7.

    Authors: Li Huang, Bin Hu, Jianbo Ni, Jianghong Wu, Weiliang Jiang, Congying Chen, Lijuan Yang, Yue Zeng, Rong Wan, Guoyong Hu and Xingpeng Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:18
  25. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-019-1210-3.

    Authors: Qi Wu, Juanjuan Li, Zhiyu Li, Si Sun, Shan Zhu, Lijun Wang, Juan Wu, Jingping Yuan, Yimin Zhang, Shengrong Sun and Changhua Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:17
  26. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-018-0875-3.

    Authors: Huaying Dong, Wei Wang, Shaowei Mo, Ru Chen, Kejian Zou, Jing Han, Fan Zhang and Jianguo Hu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:16
  27. Authors: Barbara Nuvoli, Barbara Antoniani, Roberta Libener, Antonio Maconi, Andrea Sacconi, Mariantonia Carosi and Rossella Galati
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:15

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:257

  28. Metastasis and drug resistance of breast cancer have become a barrier to treating patients successfully. Long noncoding RNAs (lncRNAs) are known as vital players in cancer development and progression. 

    Authors: Tangwei Wu, Xiaoyi Li, Ge Yan, Zheqiong Tan, Dan Zhao, Shuiyi Liu, Hui Wang, Yuan Xiang, Weiqun Chen, Hongda Lu, Xinghua Liao, Yong Li and Zhongxin Lu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:14
  29. Colorectal cancer (CRC) is the third most common cancer in the world, and a strong relationship exists between CRC and gut microbiota, which affects the occurrence, development, and metastasis of cancer. Bioin...

    Authors: Yuxiao Chang, Ziran Huang, Fengyi Hou, Yuejiao Liu, Likun Wang, Zhen Wang, Yifan Sun, Zhiyuan Pan, Yafang Tan, Lei Ding, Hong Gao, Ruifu Yang and Yujing Bi
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:13
  30. LINC00173 had been reported as a cisplatin (cis-diamminedichloroplatinum, DDP) chemotherapy-resistant inducer in small-cell lung cancer (SCLC) and lung squamous cell carcinoma (LUSC). This study aimed to display ...

    Authors: Xingyu Tao, Yang Li, Songqing Fan, Liyang Wu, Jianyang Xin, Yun Su, Xiaoyang Xian, Yingying Huang, Rongquan Huang, Weiyi Fang and Zhen Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:12
  31. CAR-T cells are widely recognized for their potential to successfully treat hematologic cancers and provide durable response. However, severe adverse events such as cytokine release syndrome (CRS) and neurotox...

    Authors: Matthew Frigault, Anand Rotte, Ayub Ansari, Bradford Gliner, Christopher Heery and Bijal Shah
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:11
  32. Posttranscriptional modification of tumor-associated factors plays a pivotal role in breast cancer progression. However, the underlying mechanism remains unknown. M6A modifications in cancer cells are dynamic ...

    Authors: Youqin Xu, Mu Song, Ziyang Hong, Wancheng Chen, Qianbing Zhang, Jianlong Zhou, Chao Yang, Zilong He, Juanjuan Yu, Xiaolin Peng, Qiuhong Zhu, Shaotian Li, Kaiyuan Ji, Minfeng Liu and Qiang Zuo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:10
  33. N4-acetylcytidine (ac4C), a widespread modification in human mRNAs that is catalyzed by the N-acetyltransferase 10 (NAT10) enzyme, plays an important role in promoting mRNA stability and translation. However, ...

    Authors: Min Deng, Long Zhang, Wenying Zheng, Jiale Chen, Nan Du, Meiqi Li, Weiqing Chen, Yonghong Huang, Ning Zeng, Yuanbin Song and Yongming Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:9
  34. Patient-derived organoids (PDOs) from advanced colorectal cancer (CRC) patients could be a key platform to predict drug response and discover new biomarkers. We aimed to integrate PDO drug response with multi-...

    Authors: Federica Papaccio, Blanca García-Mico, Francisco Gimeno-Valiente, Manuel Cabeza-Segura, Valentina Gambardella, María Fernanda Gutiérrez-Bravo, Clara Alfaro-Cervelló, Carolina Martinez-Ciarpaglini, Pilar Rentero-Garrido, Sheila Zúñiga-Trejos, Juan Antonio Carbonell-Asins, Tania Fleitas, Susana Roselló, Marisol Huerta, Manuel M. Sánchez del Pino, Luís Sabater…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:8
  35. Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that differs from other types of breast cancers in the faster spread and worse outcome. TNBC presented limited treatment options. BET (Bromodo...

    Authors: Teresa Rossi, Raffaella Zamponi, Mattea Chirico, Maria Elena Pisanu, Egidio Iorio, Federica Torricelli, Mila Gugnoni, Alessia Ciarrocchi and Mariaelena Pistoni
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:7
  36. Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. ...

    Authors: Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng and Chuanyong Guo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:6
  37. Hepatocellular carcinoma (HCC) is a multifactor-driven malignant tumor with rapid progression, which causes the difficulty to substantially improve the prognosis of HCC. Limited understanding of the mechanisms...

    Authors: Hui Zhou, Junru Chen, Mingjie Fan, Huajian Cai, Yufei Dong, Yue Qiu, Qianqian Zhuang, Zhaoying Lei, Mengyao Li, Xue Ding, Peng Yan, Aifu Lin, Shusen Zheng and Qingfeng Yan
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:5
  38. Immune-related adverse events (irAEs) are a common phenomenon in cancer patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of these irAEs have not been illustrated cl...

    Authors: Fan Yang, Chloe Shay, Marin Abousaud, Chris Tang, Yamin Li, Zhaohui Qin, Nabil F. Saba and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:4
  39. Excess body weight has been found to associate with an increased risk of lymphomas and some metabolic pathways are currently recognized in lymphomagenesis. Bioactive lipid metabolites such as sphingosine-1-pho...

    Authors: Xingtong Wang, Wei Guo, Xiaoju Shi, Yujia Chen, Youxi Yu, Beibei Du, Min Tan, Li Tong, Anna Wang, Xianying Yin, Jing Guo, Robert C. Martin, Ou Bai and Yan Li
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:3
  40. PCSK9 regulates cholesterol homeostasis and promotes tumorigenesis. However, the relevance of these two actions and the mechanisms underlying PCSK9’s oncogenic roles in melanoma and other cancers remain unclear.

    Authors: Yan Gu, Xiaozeng Lin, Ying Dong, Geoffrey Wood, Nabil G. Seidah, Geoff Werstuck, Pierre Major, Michael Bonert, Anil Kapoor and Damu Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:2
  41. Enolase 2 (ENO2) is a crucial glycolytic enzyme in cancer metabolic process and acts as a “moonlighting” protein to play various functions in diverse cellular processes unrelated to glycolysis. ENO2 is highly ...

    Authors: Lixia Gao, Fan Yang, Dianyong Tang, Zhigang Xu, Yan Tang, Donglin Yang, Deping Sun, Zhongzhu Chen and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:1
  42. Recently genome-based studies revealed that the abnormality of Hippo signaling is pervasive in TNBC and played important role in cancer progression. RING finger protein 31 (RNF31) comes to RING family E3 ubiqu...

    Authors: Huijie Yang, Min Xue, Peng Su, Yan Zhou, Xin Li, Zhongbo Li, Yan Xia, Chenmiao Zhang, Mingxi Fu, Xiuxia Zheng, Guosheng Luo, Tian Wei, Xinxing Wang, Yinlu Ding, Jian Zhu and Ting Zhuang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:364
  43. Sushi domain-containing protein 4 (SUSD4) is a recently discovered protein with unknown cellular functions. We previously revealed that SUSD4 can act as complement inhibitor and as a potential tumor suppressor.

    Authors: Konstantinos S. Papadakos, Alexander Ekström, Piotr Slipek, Eleni Skourti, Steven Reid, Kristian Pietras and Anna M. Blom
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:363
  44. The standard therapies in lymphoma have predominantly focused on targeting tumor cells with less of a focus on the tumor microenvironment (TME), which plays a critical role in favoring tumor growth and surviva...

    Authors: Wern Lynn Ng, Stephen M. Ansell and Patrizia Mondello
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:362
  45. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-018-0681-y.

    Authors: Qiaoge Zhang, Ge Song, Lili Yao, Yankun Liu, Min Liu, Shengping Li and Hua Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:361
  46. Cellular senescence is a state of stable cell-cycle arrest with secretory features in response to cellular stress. Historically, it has been considered as an endogenous evolutionary homeostatic mechanism to el...

    Authors: Andreas Domen, Christophe Deben, Jasper Verswyvel, Tal Flieswasser, Hans Prenen, Marc Peeters, Filip Lardon and An Wouters
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:360
  47. Authors: Yuan Zhou, Haozhen Ren, Bo Dai, Jun Li, Longcheng Shang, Jianfei Huang and Xiaolei Shi
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:359

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:324

  48. IFN-γ is a key mediator of tumor immunity that can induce macrophage polarization to suppress tumor growth. Cyclin G2 functions as a tumor suppressor in various cancer cells; however, its role in macrophages r...

    Authors: Lu Liu, Jinlan Gao, Xuesha Xing, Meixi Jiang, Qi Liu, Shusen Wang and Yang Luo
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:358

Annual Journal Metrics